Polmacoxib has been used in trials studying the treatment of Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Localized Primary Osteoarthritis of Hip, and Localized Primary Osteoarthritis of Knee. It is grouped under the following drug class(es): Cyclooxygenase‑2 (COX‑2) Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAID). Its therapeutic use is listed as antirheumatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include polmacoxibum and Acelex (S. Korea). Its PubChem CID is 9841854.
Polmacoxib
| CAS No | 301692-76-2 |
|---|---|
| Molecular Formula | C18H16FNO4S |
| Molecular Weight | 361.4 g/mol |
| Synonyms | 4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Polmacoxib has been used in trials studying the treatment of Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Localized Primary Osteoarthritis of Hip, and Localized Primary Osteoarthritis of Knee.
The listed CAS number is 301692-76-2.
The listed molecular formula is C18H16FNO4S.
The listed molecular weight is 361.4 g/mol.
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide.
The source lists polmacoxibum and Acelex (S. Korea).